Ophthalmic instrument distributor Medix21 has introduced two new AmnioTek products to New Zealand and is poised to introduce a third.
The three new processed human amniotic membrane (AM) products represent the latest regenerative biologics technology for treating the ocular surface, said Camille Furnandiz, Medix 21 Surgical New Zealand sales manager.
AM grafts’ low immunogenicity, anti-inflammatory, antimicrobial and antifibrotic properties have created increasing interest over the past 15 years and have been described as a “profound game changer,” by renowned cornea specialist Dr Ken Kenyon, associate clinical professor at Harvard Medical School and originator of the conjunctival autograph surgical procedure. “Used as a conjunctival substitute in pterygium surgery, a bio-therapeutic bandage to promote regenerative healing of corneal ulcerations, treating severe dry eye and scleral reinforcement for glaucoma tube shunt surgery, amnion has remarkably advanced the ocular surface therapy repertoire to enhance both wound healing as well as structural support.”
Delivered 100% sterile with a three-year shelf life, AmnioTek’s AM products can be stored at room temperature. AmnioTek 2 and G are now available in New Zealand and AmnioTek-C Vision will be available before the end of this year, said Furnandiz.